{"id":49488,"date":"2024-07-13T10:03:23","date_gmt":"2024-07-13T04:33:23","guid":{"rendered":"https:\/\/gomedii.com\/blogs\/english\/?p=49488"},"modified":"2024-07-29T18:14:33","modified_gmt":"2024-07-29T12:44:33","slug":"role-of-immunotherapy-in-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/gomedii.com\/blogs\/english\/technology\/role-of-immunotherapy-in-triple-negative-breast-cancer\/","title":{"rendered":"Role of Immunotherapy in Triple Negative Breast Cancer"},"content":{"rendered":"

In the world, women are diagnosed with breast cancer more often than any other cancer. A severe form of breast cancer known as <\/span>Triple Negative Breast Cancer<\/b> is caused by the absence of all three receptors.<\/span><\/p>\n

Triple negative breast cancer<\/b> (TNBC) is an assertive malignancy with few relevant targets, making treatment a challenge for a long time. In contrast to other subtypes of breast cancer (BC), it is frequently detected at an earlier age and carries a worse prognosis, a median overall survival (OS) of less than two years, in the case of a metastatic relapse. So, after tumor excision, complete therapeutic regimens have been developed to reduce the chance of recurrence.<\/span><\/p>\n

The most effective treatment for TNBC in its early stages is currently polychemotherapy. In order to assess tumor sensitivity and adjust post-operative systemic medication accordingly, it is usually given prior to surgery. Adjuvant capecitabine is highly effective because individuals who have residual illness following neoadjuvant chemotherapy are more likely to have a recurrence. Conversely, even though the risk of relapse is still clinically considerable, patients who obtain pathological complete response (pCR) during surgery should only have follow-up therapy.<\/span><\/p>\n

Not a single unique medicine has been studied in the previous few decades to improve the prognosis of early <\/span>Triple Negative Breast Cancer<\/b>, with the exception of adjuvant olaparib, which was recently licensed for use in a subset of high-risk TNBC patients who have pathogenic mutations in either the BRCA1 or BRCA2 genes. However, the advent of cancer immunotherapy is changing how the disease is treated.<\/span><\/p>\n

 <\/p>\n

Static Data on TNBC<\/b><\/h3>\n

 <\/p>\n

According to the <\/span>Global Cancer Statistics 2020<\/b>, 2,315,000 were females newly diagnosed with breast cancer but 684999 died of this disease. It is estimated that 1 percent of all the diagnosed diseases in the USA and the whole world were of breast cancer, and 7.5 million of the women who were diagnosed in the preceding five years were still alive.<\/span><\/p>\n

Currently, <\/span>breast cancer<\/b> is the most common type of cancer that is experienced all over the world. Specific receptors for progestogen and estrogen are absent in <\/span>Triple Negative Breast Cancer <\/b>along with HER2 amplification of this aggressive type of breast cancer. It contributes to 15-25% of all cases of the disease affecting the breast. TAMs, stromal fibroblasts, connective tissue, ECM, VEGF, TILs, and cytokines that support tumor cell proliferation and invasion are immunological TMEs of the tumor. This TME is involved in two capacities for the growth, dissemination, and metastasis of tumors.<\/span><\/p>\n

 <\/p>\n

Causes of Triple Negative Breast Cancer<\/b><\/h3>\n

 <\/p>\n

While the exact causes of <\/span>Triple Negative Breast Cancer<\/b> have not yet been established, attempts are being made in this direction. It is assumed to be initiated by a mutation of the tumor suppressor gene known as BRCA1. A protein that prevents the growth of cancer cells is often encoded by the BRCA1 gene. The BRCA1 gene, however, is mutated, which increases the body’s vulnerability to cancer by preventing the gene from operating correctly.<\/span><\/p>\n

 <\/p>\n

Symptoms<\/b><\/h4>\n